News Sentiment

IRWD sentiment intelligence

Ironwood Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 3.54 Week of 19 Jun 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-3.0% over one week, -9.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -3.0% Price reacting lower
Trend fit Trend inactive -9.7% over four weeks
Fair value -32.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 45
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 26
Market source 4
AD HOC NEWS 4
simplywall.st 3
Business Wire 2
MT Newswires 2
FinancialContent 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 12
Deals and strategy 5
Guidance 3
Regulatory and legal 2
Balance sheet 2
Capital return 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Stocktwits Direct company coverage

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A (IRWD) News, Articles, Events & Latest Updates

This article provides news and updates for Ironwood Pharmaceuticals Inc (IRWD), including recent financial performance and upcoming events. Despite beating Q1 earnings and revenue estimates driven by strong LINZESS sales, the stock experienced a slight dip. The company continues

Tone
Neutral 50/100
Event
Earnings
Published
09 May 2026 16:39
Source
Stocktwits
Stock Titan Direct company coverage

Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge

Ironwood Pharmaceuticals (IRWD) reported a significant financial turnaround in Q1 2026, swinging from a net loss to a profit, primarily driven by a substantial increase in LINZESS revenue. Total revenues surged to $106.5 million from $41.1 million year-over-year, leading to a dil

Tone
Positive 72/100
Event
Earnings
Published
08 May 2026 04:39
Source
Stock Titan
MSN Direct company coverage

Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04

This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 28.97%, bringing it to $7.04. The content provided is minimal, offering only this specific financial update without further details or analysis.

Tone
Positive 74/100
Event
Analyst action
Published
05 May 2026 05:39
Source
MSN
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy

Ironwood Pharmaceuticals is proposing an amendment to its Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 shares for equity awards, seeking stockholder approval at its 2026 annual meeting on June 16, 2026. The company emphasizes the necessity of this increase to

Tone
Positive 61/100
Event
Regulatory and legal
Published
28 Apr 2026 23:09
Source
Stock Titan
TradingView Direct company coverage

Book value per share of Ironwood Pharmaceuticals, Inc. Class A – SWB:I76

The article focuses on the book value per share of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76), traded on the Stuttgart Stock Exchange. It provides financial data and a general overview of the company's financials for various periods, without delving into specific numbers in

Tone
Neutral 50/100
Event
Market update
Published
28 Apr 2026 07:39
Source
TradingView
Stock Titan Direct company coverage

Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals

Bank of America Corporation has disclosed a 6.1% beneficial ownership stake in Ironwood Pharmaceuticals (NASDAQ: IRWD), totaling 9,962,355 Class A Common Stock shares. This information comes from a Schedule 13G/A filing, referencing 163,058,316 outstanding shares as of January 31

Tone
Neutral 50/100
Event
Deals and strategy
Published
27 Apr 2026 17:10
Source
Stock Titan
Stock Titan Direct company coverage

The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment

The Vanguard Group filed an amendment to its Schedule 13G/A report, declaring zero beneficial ownership of Ironwood Pharmaceuticals Inc. common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report the

Tone
Neutral 50/100
Event
Market update
Published
29 Mar 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%

Sarissa Capital Management LP and Alexander J. Denner have reduced their stake in Ironwood Pharmaceuticals (IRWD) through the sale of 6.7 million shares on March 17, 2026, for over $20.5 million. Despite the significant sale, Sarissa Capital still beneficially owns 5.6% of Ironwo

Tone
Negative 39/100
Event
Deals and strategy
Published
19 Mar 2026 22:40
Source
Stock Titan
Investing.com UK Direct company coverage

Ironwood Pharmaceuticals director Denner sells $20.5m in shares

Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility. Despite this insider sale, InvestingPro analysis suggests the stock is undervalued, and analysts like Jefferies and Citizens h

Tone
Neutral 50/100
Event
Market update
Published
18 Mar 2026 18:39
Source
Investing.com UK
Investing.com South Africa Direct company coverage

Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com

Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility but a significant yearly gain. Despite the insider sale, InvestingPro analysis indicates the stock is undervalued, and several

Tone
Neutral 50/100
Event
Market update
Published
18 Mar 2026 07:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale

Investment vehicles advised by Sarissa Capital Management LP, associated with director Alexander J. Denner, sold off 6.7 million shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A Common Stock on March 17, 2026, at prices between $3.05 and $3.31 per share. This major sale

Tone
Negative 38/100
Event
Deals and strategy
Published
18 Mar 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant

Ironwood Pharmaceuticals (IRWD) CFO Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. This award is in the form of restricted stock units, vesting in four equal installments over approximate anniversaries of the

Tone
Neutral 50/100
Event
Market update
Published
16 Mar 2026 08:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Chief Commercial Officer Tammi L. Gaskins was granted 136,612 restricted shares of Class A Common Stock as an equity award. This compensation award vests in four equal annual installments, tying the value to continued service and perf

Tone
Neutral 50/100
Event
Market update
Published
15 Mar 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award

Ironwood Pharmaceuticals (NASDAQ: IRWD) CEO Thomas A. McCourt was granted a restricted stock unit award of 409,836 shares of Class A Common Stock. This annual performance award, valued at $0 per share, vests in three equal installments on each approximate anniversary of the grant

Tone
Neutral 50/100
Event
Market update
Published
13 Mar 2026 18:09
Source
Stock Titan